Hanwha, Merck In $720 Million Deal To Sell Biosimilar Drugs Globally
June 13, 2011 at 02:34 AM EDT
SEOUL -(Dow Jones)- South Korea's Hanwha Chemical Corp. (009830.SE) said Monday it has signed a $720 million deal with a subsidiary of Merck & Co Inc. (MRK) to develop and sell its biosimilar pharmaceutical products in the global market.
